Geron to Present First Real-World RYTELO Data at EHA 2026 Congress
GERN•Geron Corporation will present the first real-world evidence study of RYTELO (imetelstat) in lower-risk myelodysplastic syndrome patients at the EHA 2026 Congress. The retrospective analysis will provide patient-level data on RYTELO’s safety and efficacy beyond clinical trials.
1. Upcoming EHA 2026 Presentation
Geron will unveil the inaugural real-world evidence study of RYTELO (imetelstat) in patients with lower-risk myelodysplastic syndromes at the European Hematology Association 2026 Congress. This retrospective analysis aims to deliver patient-level insights on treatment safety and efficacy in a broader clinical setting, potentially informing future regulatory filings and commercial strategies.
